US OptionsDetailed Quotes
BCTX240816C5000
- 0.05
- 0.000.00%
15min DelayClose Jul 22 15:58 ET
0.05High0.05Low
0.05Open0.05Pre Close50 Volume50 Open Interest5.00Strike Price250.00Turnover482.89%IV631.88%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1725Delta0.2945Gamma13.80Leverage Ratio-0.0044Theta0.0000Rho2.38Eff Leverage0.0005Vega
BriaCell Therapeutics Stock Discussion
3 MINUTES AGO, 7:56 AM EDT
VIA GLOBENEWSWIRE
BCTXBCTXW
SHARE
• Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3
• Significant reduction of "Eye-Bulging" metastatic breast cancer tumor was previously reported
• Heavily pre-treated patient had failed 8 prior regim...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, has recently reported significant positive clinical data for its lead product candidate, Bria-IMT™. This update has earned the company a reiterated "Buy" rating from HC Wainw...
No comment yet